The all-new tissue test that delivers maximum insights from minimal tissue.1
Actionable results
in 11 days2†
Broad coverage
with
Medicare patients paying $0‡
Important note: Guardant360 Tissue was developed as a Laboratory Developed Test (LDT), and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test has not been cleared or approved by the US FDA.
Multiomic insights from DNA,
RNA, and epigenomics1
Lowest sample input
with 40% fewer slides1*
*6 slides for Guardant360 Tissue vs 10 slide industry standard for NGS testing only.
†Median turnaround time from sample receipt to results.
‡For qualifying Medicare patients.